论文部分内容阅读
以顺铂为主的联合化疗治疗晚期卵巢癌,完全病理有效率大约为25%。二次探查术后残留病灶<1～2 cm,称为最小残留病灶,占卵巢癌患者的15～20%。在顺铂以后的第二线药物静脉化疗很难奏效。由于残留卵巢癌长期局限于腹腔内,腹腔内注射药物可使隐匿的病灶处于高浓度的药物之中。因此,在最小残留灶患者可获得30%的完全有效率。持续性的神经毒性和肾毒性是长期使用顺铂的主要限制性因素。碳铂(Carboplatin)系第二代铂衍生物,神经毒性和肾毒性小。本文报告1985年4月至1988年10月经腹腔注射碳铂治疗31例最小残留卵巢癌的治疗结果。 31例均经病理组织学诊断为卵巢癌。平均年龄56岁,按FIGO分期:Ⅰ～Ⅱ期2例,Ⅲ期28例,
Combined cisplatin-based chemotherapy for advanced ovarian cancer, complete pathological effective rate of about 25%. Residual lesions after secondary exploration <1 ~ 2 cm, known as the minimum residual lesions, accounting for 15 to 20% of ovarian cancer patients. The second line of intravenous chemotherapy after cisplatin is difficult to work. Due to the long-term confinement of residual ovarian cancer in the abdominal cavity, intraperitoneal injection of the drug allows the concealed lesion to be at a high concentration of the drug. Therefore, patients with minimal residual disease can get 30% of the total efficiency. Persistent neurotoxicity and nephrotoxicity are major limiting factors in the long-term use of cisplatin. Carboplatin is the second-generation platinum derivative with low neurotoxicity and nephrotoxicity. This article reports from April 1985 to October 1988 by intraperitoneal injection of carboplatin in the treatment of 31 cases of minimal residual ovarian cancer. 31 cases were diagnosed by histopathology as ovarian cancer. The average age of 56 years, according to FIGO staging: Ⅰ ~ Ⅱ in 2 cases, Ⅲ in 28 cases,